Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 148

1.

A biochemical framework for eIF4E-dependent mRNA export and nuclear recycling of the export machinery.

Volpon L, Culjkovic-Kraljacic B, Sohn HS, Blanchet-Cohen A, Osborne MJ, Borden KLB.

RNA. 2017 Jun;23(6):927-937. doi: 10.1261/rna.060137.116. Epub 2017 Mar 21.

2.

The eukaryotic translation initiation factor eIF4E wears a "cap" for many occasions.

Borden KL.

Translation (Austin). 2016 Aug 10;4(2):e1220899. doi: 10.1080/21690731.2016.1220899. eCollection 2016.

3.

Importin 8 mediates m7G cap-sensitive nuclear import of the eukaryotic translation initiation factor eIF4E.

Volpon L, Culjkovic-Kraljacic B, Osborne MJ, Ramteke A, Sun Q, Niesman A, Chook YM, Borden KL.

Proc Natl Acad Sci U S A. 2016 May 10;113(19):5263-8. doi: 10.1073/pnas.1524291113. Epub 2016 Apr 25.

4.

Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas.

Culjkovic-Kraljacic B, Fernando TM, Marullo R, Calvo-Vidal N, Verma A, Yang S, Tabbò F, Gaudiano M, Zahreddine H, Goldstein RL, Patel J, Taldone T, Chiosis G, Ladetto M, Ghione P, Machiorlatti R, Elemento O, Inghirami G, Melnick A, Borden KL, Cerchietti L.

Blood. 2016 Feb 18;127(7):858-68. doi: 10.1182/blood-2015-05-645069. Epub 2015 Nov 24.

5.

Multiple Export Mechanisms for mRNAs.

Delaleau M, Borden KL.

Cells. 2015 Aug 28;4(3):452-73. doi: 10.3390/cells4030452. Review.

6.

Molecular Pathways: GLI1-Induced Drug Glucuronidation in Resistant Cancer Cells.

Zahreddine HA, Borden KL.

Clin Cancer Res. 2015 May 15;21(10):2207-10. doi: 10.1158/1078-0432.CCR-14-1370. Epub 2015 Mar 25.

7.

Sonic Hedgehog factor Gli1: As good as resistant.

Zahreddine HA, Culjkovic-Kraljacic B, Borden KL.

Mol Cell Oncol. 2015 Feb 24;2(1):e961827. doi: 10.4161/23723548.2014.961827. eCollection 2015 Jan-Mar.

8.

The eukaryotic translation initiation factor eIF4E in the nucleus: taking the road less traveled.

Osborne MJ, Borden KL.

Immunol Rev. 2015 Jan;263(1):210-23. doi: 10.1111/imr.12240. Review.

9.

Inducible drug modification: a new form of resistance.

Culjkovic-Kraljacic B, Zahreddine HA, Borden KL.

Cell Cycle. 2014;13(16):2485-6. doi: 10.4161/15384101.2014.946372. No abstract available.

10.

When will resistance be futile?

Borden KL.

Cancer Res. 2014 Dec 15;74(24):7175-80. doi: 10.1158/0008-5472.CAN-14-2607. Epub 2014 Dec 4. Review.

11.

A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E.

Assouline S, Culjkovic-Kraljacic B, Bergeron J, Caplan S, Cocolakis E, Lambert C, Lau CJ, Zahreddine HA, Miller WH Jr, Borden KL.

Haematologica. 2015 Jan;100(1):e7-9. doi: 10.3324/haematol.2014.111245. Epub 2014 Nov 25. No abstract available.

12.

Nitrogen deposition potentially contributes to oak regeneration failure in the Midwestern temperate forests of the USA.

BassiriRad H, Lussenhop JF, Sehtiya HL, Borden KK.

Oecologia. 2015 Jan;177(1):53-63. doi: 10.1007/s00442-014-3119-z. Epub 2014 Nov 19.

PMID:
25407618
13.

MNKs act as a regulatory switch for eIF4E1 and eIF4E3 driven mRNA translation in DLBCL.

Landon AL, Muniandy PA, Shetty AC, Lehrmann E, Volpon L, Houng S, Zhang Y, Dai B, Peroutka R, Mazan-Mamczarz K, Steinhardt J, Mahurkar A, Becker KG, Borden KL, Gartenhaus RB.

Nat Commun. 2014 Nov 18;5:5413. doi: 10.1038/ncomms6413.

14.

TIF-90 tips the balance in rRNA synthesis.

Borden KL.

Blood. 2014 Jul 24;124(4):467-8. doi: 10.1182/blood-2014-06-578914. No abstract available.

15.

The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation.

Zahreddine HA, Culjkovic-Kraljacic B, Assouline S, Gendron P, Romeo AA, Morris SJ, Cormack G, Jaquith JB, Cerchietti L, Cocolakis E, Amri A, Bergeron J, Leber B, Becker MW, Pei S, Jordan CT, Miller WH, Borden KL.

Nature. 2014 Jul 3;511(7507):90-3. doi: 10.1038/nature13283. Epub 2014 May 28.

16.

LIMD2 is a small LIM-only protein overexpressed in metastatic lesions that regulates cell motility and tumor progression by directly binding to and activating the integrin-linked kinase.

Peng H, Talebzadeh-Farrooji M, Osborne MJ, Prokop JW, McDonald PC, Karar J, Hou Z, He M, Kebebew E, Orntoft T, Herlyn M, Caton AJ, Fredericks W, Malkowicz B, Paterno CS, Carolin AS, Speicher DW, Skordalakes E, Huang Q, Dedhar S, Borden KLB, Rauscher FJ 3rd.

Cancer Res. 2014 Mar 1;74(5):1390-1403. doi: 10.1158/0008-5472.CAN-13-1275.

17.

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators.

N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839.

18.

Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.

Clozel T, Yang S, Elstrom RL, Tam W, Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B, Scott DW, Wyman S, Leser M, Shaknovich R, Chadburn A, Tabbo F, Godley LA, Gascoyne RD, Borden KL, Inghirami G, Leonard JP, Melnick A, Cerchietti L.

Cancer Discov. 2013 Sep;3(9):1002-19. doi: 10.1158/2159-8290.CD-13-0117. Epub 2013 Aug 16.

19.

eIF4E3, a new actor in mRNA metabolism and tumor suppression.

Volpon L, Osborne MJ, Culjkovic-Kraljacic B, Borden KL.

Cell Cycle. 2013 Apr 15;12(8):1159-60. doi: 10.4161/cc.24566. Epub 2013 Apr 9. No abstract available.

20.

Conformational changes induced in the eukaryotic translation initiation factor eIF4E by a clinically relevant inhibitor, ribavirin triphosphate.

Volpon L, Osborne MJ, Zahreddine H, Romeo AA, Borden KL.

Biochem Biophys Res Commun. 2013 May 10;434(3):614-9. doi: 10.1016/j.bbrc.2013.03.125. Epub 2013 Apr 10.

Supplemental Content

Loading ...
Support Center